GlassScriptPhysician profile
Christopher Tsung Lung Ho
NPI 1679507537
$730,511.29
in general payments reported to CMS, 2019-2025
34 companies · $22K in 2025
The $22K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206K · 2020: $78K · 2021: $134K · 2022: $135K · 2023: $102K · 2024: $55K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Consulting Fee: $10K · Travel and Lodging: $4,636 · Food and Beverage: $3,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $159,730.87 |
| Consulting Fee | $10,288.45 |
| Travel and Lodging | $4,636.38 |
| Food and Beverage | $3,906.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $307,440.76 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $168,769.84 | 2019-2024 | |
| Celgene Corporation | $98,136.45 | 2019 | |
| Pfizer INC. | $58,035.24 | 2019-2025 | |
| Lilly USA, LLC | $43,874.17 | 2019-2023 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $20,764.03 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $16,412.61 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $8,554.53 | 2019-2022 | |
| Dermavant Sciences, INC. | $2,700.20 | 2022-2023 | Vtama |
| Ucb, INC. | $2,637.77 | 2019-2023 | Cimzia |
| Genzyme Corporation | $583.25 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $456.61 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $454.81 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $373.17 | 2019 | |
| Janssen Biotech, INC. | $322.63 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $241.24 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Epi Health, LLC | $213.35 | 2019-2020 | |
| Journey Medical Corporation | $116.47 | 2021-2022 | |
| Galderma Laboratories, L.P. | $95.39 | 2019-2020 | |
| Leo Pharma INC. | $83.24 | 2020-2022 | |
| Dermira, INC. | $56.09 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $40.94 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.15 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.13 | 2022 | |
| Merck Sharp & Dohme LLC | $17.95 | 2019 | |
| Almirall LLC | $16.71 | 2021 | |
| Merz North America, INC. | $13.90 | 2019 | |
| Allergan, INC. | $12.10 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.